In December 2012, the US Drug Enforcement Administration proposed classifying<unk>  as a Schedule IV drug because it has hallucinogenic properties at higher than approved doses and users could develop psychiatric dependencies on the drug. On 7 May 2013, the US Drug Enforcement Administration classified<unk>  as a Schedule IV drug under the Controlled Substances Act. There has been concern that<unk>  can cause cardiac valvulopathy based upon the reports of subjects taking the drug in Phase 2 trials. However, a Phase 3 clinical trial of the drug was conducted and the results published in the October 2014 Postgraduate Medicine journal, a peer-reviewed medical journal for physicians. These results found no statistically significant differences in valvulopathy rates compared to control, being 2.4% for the drug subjects and 2.0% for controls, and concluded that the drug is safe for the target population although more long-term data is needed. A drug safety communication from the US Food and Drug Administration (FDA), in January 2020, stated that a clinical trial demonstrated a possible increased risk of cancer for those taking<unk> . The FDA approval of<unk>  required the manufacturer to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. The trial was conducted in approximately 12,000 participants over five years and more patients taking<unk>  were diagnosed with cancer compared to patients taking placebo. In February 2020, the FDA requested that the manufacturer<unk>  voluntarily withdraw the drug from the US market because a safety clinical trial showed an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
Lorcaserin
Pegvisomant
Tegaserod
Romidepsin
Nizatidine
Lansoprazole
Dexlansoprazole
Degmacyte